Riskpilot← Back to searchSign inGet full accessDIAG NOR AS
ASActiveOrg 947992333Drengsrudbekken 9, 1383 AskerWholesale of pharmaceutical and medical goods · NACE 4646Est. 19880 employees
Revenue 2025
NOK 406K
+60% vs 2024
EBITDA margin
28.6%
+152% vs 2024
Equity ratio
74.6%
Financial strength
Net profit 2025
NOK 88K
+150% vs 2024
| Revenue | NOK 406K | +60% |
| EBITDA | NOK 116K | +152% |
| Net profit | NOK 88K | +150% |
| Total assets | NOK 770K | +1% |
| Equity | NOK 575K | +18% |
| Employees | 0 | — |
Legal name
DIAG NOR AS
Org number
947992333
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. mai 1988
Share capital
—
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Produksjon av reagenser og innkjøp av nødvendige råvarer i denne forbindelse.
Address
Drengsrudbekken 9, 1383 Asker
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 013 | 524 | 446 | 254 | 406 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 50 | 179 | 18 | −224 | 116 |
| Depreciation & amort. | −10 | −10 | −3 | −0 | −0 |
| EBIT | 40 | 169 | 15 | −224 | 116 |
| Net financials | −1 | −1 | −2 | −2 | −3 |
| Profit before tax | 38 | 168 | 13 | −225 | 113 |
| Tax | 8 | 37 | 3 | −50 | 25 |
| Net profit | 30 | 131 | 10 | −176 | 88 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 767 | 850 | 846 | 765 | 770 |
| Equity | 334 | 465 | 476 | 486 | 575 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 433 | 385 | 370 | 278 | 196 |
| Total debt | 433 | 385 | 370 | 278 | 196 |
EBITDA margin
28.6%
This company
15.8%
Market median
+81% vs market
20212025
Equity ratio
74.6%
This company
38.2%
Market median
+95% vs market
20212025
Return on equity
15.4%
This company
18.4%
Market median
+16% vs market
20212025
Net profit margin
21.8%
This company
8.1%
Market median
+169% vs market
20212025
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20212025
Debt / equity
0.34×
This company
0.62×
Market median
+45% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KS Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
BE Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Chairman | 2024 – 2025 | |
| Chairman | 2018 – 2022 | |
| Chairman | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 91.96% | 91.96% | 2024 | |
| Individual | 4.02% | 4.02% | 2024 | |
| Individual | 4.02% | 4.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Med-Hold As
DIAG NOR AS Board members of DIAG NOR AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjørn Egil Ludvigsen | Chief Executive Officer | 0 companies |
| Karin Stangeland | Chief Executive Officer | 0 companies |
| Jon Terje Heimdal | Chairman | 0 companies |
| Olaf Jørgen Styrmoe | Chairman | 0 companies |
| Jens Ragnar Jensen | Chairman | 0 companies |